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Abstract
To systematically review clinical and health economic impacts of treat-to-target (TTT) strategies in patients with rheumatoid
arthritis (RA) managed in specialist units, compared with routine care. Sixteen and seven electronic databases were searched for
clinical RCTs and cost-effectiveness respectively. Study selection, data extraction and quality assessment (Cochrane
Collaboration risk of bias criteria) were performed. Evidence was reported by (1) TTT vs. usual care; (2) comparison of different
treatment protocols against each other; (3) comparison of different targets against each other. Narrative synthesis was undertaken
and conclusions drawn on a trial by trial basis, due to study heterogeneity. Twenty-two RCTs were included. Sixteen were at high
risk of bias, five unclear and one low risk. Three trials showed TTT to be more effective than usual care in terms of remissions, in
some or all comparisons, whereas one other trial reported no significant difference. Two trials showed TTT to be more effective
than usual care in terms of low disease activity (LDA), in some or all comparisons, whereas two trials reported little difference.
Some evidence suggests that TTT strategies involving combination therapy can achieve more remissions than those involving
monotherapy, but little impact of alternative treatment targets on remission or LDA. Overall, there is evidence that TTT increases
remissions in early RA and mixed early and established RA populations, and increases LDA in established RA. Although results
varied, typically TTT was estimated to be more cost-effective than usual care. No target appears more effective than others.
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Introduction
Rheumatoid arthritis (RA), characterised by persisting joint
inflammation and pain, leads to joint damage, disability and
poor quality of life, which incur high medical and societal
costs [1–4]. In developed countries, between 0.5 and 1% of
adults have RA, and its long-term course means its prevalence
rises with age [5].
Drug treatment for RA over the last two decades has fo-
cused on using disease-modifying anti-rheumatic drugs
(DMARDs) with variable amounts of short-term glucocorti-
coids. Conventional synthetic DMARDs (csDMARDs), such
as methotrexate, are widely used. They are often supplement-
ed by biological DMARDs (bDMARDs), in particular tumour
necrosis factor inhibitors such as etanercept [6]. bDMARDs
are substantially more expensive than csDMARDs and are
usually given in combination with methotrexate [7]. An addi-
tional new group of DMARDs, the Janus kinase inhibitors,
has been available for a few years, but their use is minimal in
the trial designs included in our systematic review.
The goal of DMARD treatment is to reduce disease activ-
ity, ideally by achieving remission or low disease activity
(LDA). As csDMARD and bDMARDs can be used in com-
bination and doses adjusted according to clinical response, the
concept of “treat-to-target” (TTT) has grown in recent years,
supported by international reports and guidelines [8–12]. Its
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components comprise (a) setting the target, which is usually
remission or LDA; (b) assessing disease activity every 1–3
months using measures like the disease activity score for 28
joints (DAS28); and (c) increasing csDMARDs, bDMARDs,
and Janus kinase inhibitors to facilitate achievement of the
target, using short-term glucocorticoids if needed [7]. As
TTT is a relatively new strategy, there is uncertainty about
both its efficacy and its cost-effectiveness, although economic
analysis using observational data provides some support [13].
bDMARDs are expensive drugs and their use in TTT in-
curs high costs to healthcare providers. There is consequently
a strong case to assess the underlying health economic ratio-
nale for using TTT approaches. As the impact of TTT differs
in early and established RA patients [8, 10], economic evalu-
ations need to consider these populations separately. Although
systematic reviews by Schoels et al. [9] and Stoffer et al. [11]
assessed the evidence supporting TTT, neither evaluated its
economic impact. There have also been several new trials
reported since these reviews were completed. We have con-
sequently undertaken a comprehensive systematic review of
both the clinical and health economic impacts of TTT, includ-
ing randomised controlled trials (RCTs) published up until
2020.
Methods
This review was commissioned by the NIHR HTA
Programme (Project 14/17/01) [14]. The protocol is registered
as PROSPERO CRD42015017336.
Search Strategy
We followed PRISMA principles (http://www.prisma-
statement.org/) (Supplement 1).
Initial searches involved MEDLINE, EMBASE, Cochrane
Database of Systematic Reviews, Cochrane Central Register
of Controlled Trials (CENTRAL), NHS Economic Evaluation
Database (NHS EED), Health Technology Assessment
Database (HTA), Database of Abstracts of Reviews of
Effects (DARE), Web of Science Citation Index Expanded
(WoS), Web of Science Citation Index and Conference
Proceedings Index (WoS-CPI), EULAR (via Web of
Science), ACR (via Web of Science) and ClinicalTrials.gov
using terms for RA combined with TTT terms (after Schoels
et al. [9]), and search filters for RCTs, systematic reviews and
economic evaluations (Supplement 2).
A full systematic search was conducted from database in-
ception to January 2016, refined by initial searches, on
MEDLINE, EMBASE, CENTRAL, NHS EED, WoS, WoS-
CPI, BIOSIS Previews, CINAHL, Econlit, ClinicalTrials.gov,
International Clinical Trials Registry Platform and NICE
Evidence. Additional TTT and RCT free-text terms and
economic evaluation filters were added (Supplement 2) to
increase the search sensitivity. No date or language limits
were applied. Records from initial and full searches were com-
bined and duplicates removed. An update search was per-
formed on Medline (via EbscoHOST) in November 2020.
No date or language limits were applied. The results from
the update search were de-duplicated against the original
results.
Inclusion and Exclusion Criteria
RCTs (including cluster RCTs) examining the effectiveness of
one or more TTT strategies to guide treatment decisions for
individual patients compared with (1) usual care (no TTT
strategies); (2) TTT strategy using an alternative treatment
protocol; and (3) TTT strategy using an alternative target, on
the proportion of patients achieving remission and LDA, and
adverse effects, among adults with clinically diagnosed RA
managed anywhere on the treatment pathway, were included.
Sufficient description of the TTT strategy was required; meet-
ing abstracts had to contain sufficient methodological details
for critically appraising study quality. Included studies were
limited to those published in the English language. Animal
models, preclinical and biological studies, trials of
personalised medicine, trials of other designs and trials de-
signed to test an active drug against placebo, where both/all
trial arms pursue the same target and treatment protocol, were
excluded.
Study Selection and Data Extraction
One reviewer (MMSJ) examined titles and abstracts of re-
trieved records; 5% were checked by another reviewer
(ESH). Full texts of all studies included were examined by
two reviewers, where necessary discrepancies were resolved
by discussion involving a third reviewer. For the update
search, all titles, abstracts and full texts were examined by
one reviewer (ESH) and checked by another (ELS or MMSJ).
Three reviewers undertook data extraction (ESH, MMSJ,
ELS). Each paper was extracted by one reviewer, unblinded to
authors or journal, on data relevant to the decision problem,
using a standardised form. Data on study, population and TTT
characteristics, including adverse events (AEs), were extract-
ed and checked by a second reviewer. Discrepancies were
discussed and agreement was reached without needing to con-
sult a third reviewer.
Quality Assessment
One reviewer (shared among ESH, MMSJ, ELS) assessed
methodological quality of each RCT using Cochrane
Collaboration risk of bias assessment criteria, evaluating se-
quence generation; allocation concealment; blinding of
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participants and personnel; blinding of outcome assessment;
incomplete outcome data; and selective outcome reporting,
each judged as high, low or unclear risk of bias [15]. We
included three additional domains for cluster RCTs: recruit-
ment bias (whether participants were recruited prior to clusters
being randomised); risk of baseline differences between clus-
ters; and attrition of clusters. We classified RCTs as overall
‘low risk’ of bias if they were rated as ‘low’ for each of three
key domains—allocation concealment, blinding of outcome
assessment and completeness of outcome data (> 10% attri-
tion [16]). RCTs at ‘high risk’ of bias for any of these domains
were judged ‘high risk’ overall. RCTs neither being at ‘high
risk’ for any domain, nor ‘low risk’ for all these domains, were
judged ‘unclear risk’ overall. All quality assessments were
checked by a second reviewer with discrepancies discussed
and agreement reached.
Data Synthesis
Evidence of clinical effectiveness of TTT was organised by
TTT comparisons: (1) TTT vs. usual care; (2) comparison of
different treatment protocols; (3) comparison of different tar-
gets. Two trials not fitting this framework were examined
separately [17–20]. Some trials made more than one compar-
ison and appear under more than one category. Trials were
further examined according to whether they used early or
established RA populations [8, 10, 21] using definitions of
early and established RA outlined in the trials; where no def-
inition was provided a 3-year cut-off was used [21].
Results
Study Selection
Forty-nine papers reporting 22 RCTs were included from
17,631 records reviewed (Fig. 1); 42 papers reporting 16
RCTs from the original searches, and seven papers reporting
six new RCTs and one updated RCT from the update
searches. We excluded 17,418 on titles and abstracts: 213
publications were reviewed in detail and 164 papers describ-
ing 72 studies were excluded (107 not TTT, 18 not RCTs; 10
reporting no relevant outcomes; 29 excluded for diverse
reasons).
Study Characteristics
The 49 papers described 22 trials of 5990 RA patients. The
trials spanned four categories (Table 1) based on their main
features. Eight trials (1977 patients) compared TTT with usual
care [22–29]; seven trials (2418 patients) compared different
treatment protocols [30–36]; six trials (1758 patients) com-
pared different treatment targets [24, 26, 35, 37–39]; four trials
(1143 patients) made other comparisons of conventional with
intensive therapy [14, 17, 19, 20]. Thirteen trials studied early
RA patients [17, 24, 25, 30–39]; five studied established RA
patients [19, 26–28, 40]; and four studied early and
established RA [20, 22, 23, 29]. Fifteen trials involved con-
trols receiving less intensive treatment [17, 19, 20, 22–30, 33,
36, 40], including four with groups receiving different inten-
sive treatment strategies [24, 26, 30, 36]. Five trials compared
different intensive treatments without controls receiving less
intensive therapy [30–32, 34, 35]. Three trials compared two
different targets without controls receiving less intensive ther-
apy [37–39]. Four trials were cluster randomised [22, 26, 27,
29] and 18 were not [17, 19, 20, 23–25, 28, 30–40].
Risk of Bias
Twelve RCTs were judged at overall high risk of bias [17, 19,
20, 24, 28, 31, 33, 35–39], five at overall unclear risk of bias
[25, 30, 32, 34, 40] and one at overall low risk of bias [23].
None were judged at high risk of bias for random sequence
generation or allocation concealment; 13 had high risk of bias
for blinding of participants and personnel [17, 19, 20, 23–25,
31–34, 38–40]; eight for blinding of outcome assessment [19,
20, 24, 31, 33, 37–39]; eight from reporting withdrawals >
10% [17, 19, 24, 28, 35, 36, 39, 40]; and five had high risk of
bias as some outcomes reported in either the protocol [20, 25,
28, 32] or the methods section [35] were omitted from the
results (Supplement 3).
All four cluster RCTs were considered at overall high risk
of bias [22, 26, 27, 29]. Three were judged at high risk of bias
for blinding of participants and personnel [22, 26, 27], one had
high risk of bias for blinding of outcome assessment [22], all
four had high risk of attrition bias [22, 26, 27, 29], one had
high risk of bias for selective reporting [26], two had high risk
of cluster recruitment bias (participants were recruited after
clusters were randomised) [26, 27] and two had high risk of
bias for cluster attrition (outcomes were limited to a subset of
original clusters randomised) [27, 29] (Supplement 3).
Clinical Effectiveness
Heterogeneity across populations, comparisons, targets, treat-
ment protocols and outcomes precluded meta-analysis. Trial
findings were synthesised narratively focusing on proportions
of patients achieving end-point remissions in 18 trials, and
LDA or equivalent in four trials not reporting remissions
(Table 2 and Fig. 2).
TTT vs Usual Care
Four of the eight trials reported remissions: all found more
remissions with intensive treatment; differences were signifi-
cant in three trials. The TICORA trial [23] (two groups, early
SN Compr. Clin. Med.
and established RA, 18-month treatment) reported the largest
difference (intensive treatment 65%, conventional treatment
16%, p < 0.001). The T-4 trial [24] (four groups, early RA,
12-month treatment) reported a significant difference with
DAS28-driven care compared with conventional treatment
(38% vs 21%, p = 0.05). The Optimisation of Adalimumab
trial [26, 41] (three groups, established RA, 18-month treat-
ment) reported a significant difference between DAS28-
driven care and conventional treatment (38% vs 16%, p =
0.027) in the ITT analysis but the completer analysis showed
no significant difference. The STREAM trial [25] (two
groups, early RA, 2-year treatment) reported more remissions
with intensive than conventional treatment (66% vs 49%); this
difference was not significant.
The Fransen trial [27] (two groups, established RA, 6-
month treatment) only reported LDA; significantly more pa-
tients achieved LDA with intensive than conventional treat-
ment (31% vs 16%, p = 0.028). Similarly, the Bergsten trial
[28] reported a greater proportion of patients achieved LDA
with intensive (48%) than conventional treatment (24%). The
van Hulst trial [22] (two groups, early and established RA, 18-
month treatment) reported more EULAR good responders
(which includes LDA) with intensive (22%) than
conventional treatment (18%) (significance unreported). In
the Harrold trial [29], a similar proportion of patients achieved
LDA with intensive (57%) and conventional treatment (55%).
Comparison of Treatment Protocols
All seven trials reported remissions [30–36]. Two trials in-
volving conventionally treated controls reported significantly
more remissions with intensive treatments. The U-Act-Early
trial [36] (three groups, early RA, 24-month treatment) report-
ed significantly more remissions with tocilizimab and metho-
trexate (86%) than methotrexate monotherapy (44%, p <
0.001). The FIN-RACo trial [33] (two groups, early RA, 24-
month treatment) reported 37% remissions with intensive
combinations and 18% remissions with monotherapy (p =
0.003).
Five trials compared different intensive treatment regi-
mens. They comprised the BeSt trial [30, 42] (four groups,
early RA, 12-month treatment), the CareRA trial [43, 44] (five
groups, early RA, 24-month treatment), the COBRA-light tri-
al [45] (two groups, early RA, 12-month treatment), the
Saunders trial [34] (two groups, early RA, 12-month treat-
ment) and the TEAR trial [35] (four groups, early RA, 24-
Fig. 1 Flow diagram of study
selection for systematic review of
TTT strategies in rheumatoid
arthritis
LDA low disease activity, RCT
randomised controlled trial, TTT
treat-to-target
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Table 2 Targets, low disease activity and remission for TTT strategies in RA
Trial Treatments Cases Follow-
up
months
Number completing (%) Target Number (%) meeting
trial target
Number (%) LDA Number (%)
remission
TTT vs usual care
STREAM [25] Conventional 40 24 38/40 (95%) None 19/40 (49%) NR 19/40 (49%)
Aggressive 42 24 41/42 (98%) Remission (DAS44 < 1.6) 27/42 (66%) NR 27/42 (66%)
T-4 Study [24] Routine 62 12 55/62 (89%) None NA NR 13/62 (21%)
MMP-3-driven 60 12 53/60 (88%) Low MMP-3 NR NR 8/60 (13%)
DAS28-driven 60 12 56/60 (93%) DAS28 < 2.6 23/60 (38%) NR 23/60 (38%)
DAS28 and MMP-3-driven 61 12 58/61 (95%) DAS28 < 2.6 and low
MMP-3
NR NR 34/61 (56%)
Fransen [27] Usual care 179 6 159/179 (89%) None 13/81 (16%) 13/81 (16%) NR
DAS28 target 205 6 189/205 (82%) DAS28 ≤ 3.2 19/61 (31%) 19/61 (31%) NR
Optimisation of
Adalimumab [26, 41]
Routine care 109 18 52/109 (48%) None 16% (DAS28 < 2.6);
21% (SJC = 0)
25/109 (23%) 17/109 (16%)
SJC target 99 18 77/99 (78%) SJC of 0 26/99 (26%) 27/99 (27%) 22/99 (22%)
DAS28 target 100 18 73/100 (73%) DAS28 < 2.6 38/100 (38%) 47/100 (47%) 38/100 (38%)
TICORA [23] Routine 55 18 50/55 (91%) None NR 24/55 (44%)a 9/55 (16%)
Intensive 55 18 53/55 (96%) DAS44 ≤ 2.4 NR 45/55 (82%)a 36/55 (65%)
Van Hulst [22] Usual care 104 18 92/104 (88%) None NR 19/104 (18%)a NR
Intervention 144 18 138/144 (96%) DAS28 ≤ 3.2 NR 30/134 (22%)a NR
Bergsten [28] Regular care 34 6 33/34 (97%) None NR 8/33 (24%) NR
Intervention 36 6 29/36 (81%) DAS28 < 2.6 NR 14/29 (48%) NR
Harrold [29] Usual care 286 12 239/286 (84%) None 156/286 (55%) 156/286 (55%) NR
CDAI target 246 12 197/246 (80%) CDAI ≤ 10 139/246 (57%) 139/246 (57%) NR
Comparison of treatment protocols
BeSt [30] Sequential monotherapy 126 12 122/126 (97%) DAS44 ≤ 2.4 63/118 (53%) 63/118 (53%) 36/126 (29%)
Step-up combination 121 12 115/121 (95%) DAS44 ≤ 2.4 72/112 (64%) 72/112 (64%) 35/121 (29%)
Initial prednisone combination 133 12 128/133 (96%) DAS44 ≤ 2.4 87/122 (71%) 87/122 (71%) 44/133 (33%)
Initial infliximab combination 128 12 126/128 (98%) DAS44 ≤ 2.4 89/121 (74%) 89/121 (74%) 45/128 (36%)
CareRA: high-risk
[43, 44, 56, 57]
COBRA Classic 98 24 85/98 (87%) DAS28-CRP ≤ 3.2 86/98 (88%) 86/98 (88%) 64/98 (65%)
COBRA Slim 98 24 87/98 (89%) DAS28-CRP ≤ 3.2 86/98 (88%) 86/98 (88%) 71/98 (72%)
COBRA Avant-Garde 93 24 77/93 (83%) DAS28-CRP ≤ 3.2 85/93 (91%) 85/93 (91%) 69/93 (74%)
CareRA: low-risk
[43, 44, 54, 55]
MTX-TSU 47 24 41/47 (87%) DAS28-CRP ≤ 3.2 41/47 (87%) 41/47 (87%) 34/47 (72%)
COBRA Slim 43 24 32/43 (74%) DAS28-CRP ≤ 3.2 36/43 (84%) 36/43 (84%) 29/43 (67%)
COBRA-Light [32, 45] COBRA 81 12 78/81 (96%) DAS44 < 1.6 38/81 (47%) 56/81 (69%) 38/81 (47%)
COBRA-light 83 12 77/81 (95%) DAS44 < 1.6 31/81 (38%) 49/83 (60%) 31/81 (38%)
FIN-RACo [33] Single-drug treatment 100 24 91/98 (93%) Remission 18/100 (18%) NR 18/98 (18%)
Combination treatment 99 24 87/97 (90%) Remission 36/99 (37%) NR 36/97 (37%)
Saunders [34] Parallel triple therapy 49 12 47/49 (96%) DAS28 < 3.2 20/49 (41%) 20/49 (41%) 16/49 (33%)
Step-up therapy 47 12 44/47 (94%) DAS28 < 3.2 28/47 (60%) 28/47 (60%) 21/47 (45%)
TEAR [35] Step-up triple therapy 124 24 81/124 (65%) DAS28-ESR < 3.2 at 6 months 106/379 (28%) [data
combined for step-up arms]
NR 42/75 (57%)
Step-up ETN 255 24 182/255 (71%) DAS28-ESR < 3.2 at 6 months NR 88/166 (53%)
Immediate triple therapy 132 24 82/132 (62%) None 57/132 (43%) NR 45/76 (59%)
Immediate ETN 244 24 168/244 (69%) None 100/244 (41%) NR 90/159 (57%)
U-Act-Early [36] MTX 108 24 78/108 (72%) DAS28 < 2.6 83/108 (77%) NR 48/108 (44%)
Tocilizumab 103 24 81/103 (79%) DAS28 < 2.6 91/103 (88%) NR 86/103 (83%)













Trial Treatments Cases Follow-
up
months
Number completing (%) Target Number (%) meeting
trial target
Number (%) LDA Number (%)
remission
Comparison of different targets
Hodkinson [27] SDAI arm 42 12 41/42 (98%) SDAI ≤ 11 NR 27/42 (64%) 14/42 (34%)
CDAI arm 60 12 57/60 (95%) CDAI ≤ 10 NR 38/60 (63%) 19/60 (33%)
T-4 Study [24] Routine 62 12 55/62 (89%) None NA NR 13/62 (21%)
MMP-3-driven 60 12 53/60 (88%) Low MMP-3 NR NR 8/60 (13%)
DAS28-driven 60 12 56/60 (93%) DAS28 < 2.6 23/60 (38%) NR 23/60 (38%)
DAS28 and MMP-3-driven 61 12 58/61 (95%) DAS28 < 2.6 and low MMP-3 NR NR 34/61 (56%)
Optimisation of
Adalimumab [26, 41]
Routine care 109 18 52/109 (48%) None 16% (DAS28 < 2.6);
21% (SJC=0)
25/109 (23%) 17/109 (16%)
SJC target 99 18 77/99 (78%) SJC of 0 26/99 (26%) 27/99 (27%) 22/99 (22%)
DAS28 target 100 18 73/100 (73%) DAS28 < 2.6 38/100 (38%) 47/100 (47%) 38/100 (38%)




Step-up ETN 255 24 182/255 (71%) DAS28-ESR < 3.2 at 6 months NR 88/166 (53%)
Immediate triple therapy 132 24 82/132 (62%) None 57/132 (43%) NR 45/76 (59%)
Immediate ETN 244 24 168/244 (69%) None 100/244 (41%) NR 90/159 (57%)
Tam [38] SDAI target 60 12 54/60 (90%) SDAI ≤ 3.3 21/57 (37%) 43/57 (75%)a 29/57 (51%)
DAS28 target 60 12 56/60 (93%) DAS28-CRP < 2.6 33/60 (55%) 41/60 (68%)a 33/60 (55%)
ARCTIC [39] Conventional tight control 118 24 110/112 (89%) DAS44 < 1.6 & SJC = 0 NR NR 75/112 (67%)
Ultrasound tight control 112 24 104/118 (88%) No PD signal in any joint +
DAS44 < 1.6 & SJC = 0
NR NR 80/118 (68%)
Other comparisons
CAMERA [17] Conventional strategy 148 24 113/148 (76%) None NR NR 55/148 (37%)
Intensive strategy 151 24 92/151 (61%) Computer decision NR NR 76/151 (50%)
BROSG [18, 40] Symptomatic 233 36 197/233 (85%) Control symptoms NR NR 23/233 (14%)
Aggressive 233 36 202/233 (87%) Control symptoms/suppress
inflammation
NR NR 34/233 (20%)
TITRATE [19] Standard care 167 12 124/167 (74%) None 30/167 (18%) 53/167 (32%) 30/167 (18%)
Intensive Management 168 12 134/168 (80%) Shared decision between
patient and nurse
54/168 (32%) 81/168 (48%) 54/168 (32%)
Mueller [20] Fixed regimen including
certolizumab pegol
22 6 21/22 (95%) None 8/22 (36%) NR 29%
TTT including certolizumab
pegol
21 6 19/21 (90%) ACR50 16/21 (76%) NR 68%
Abbreviations: CDAI Clinical Disease Activity Index; COBRA COmBination theRApy with rheumatoid arthritis; DAS28 Disease Activity Score, 28 joints; DAS28-CRP Disease Activity Score, 28 joints
with C-reactive protein concentration; DAS28-ESR Disease Activity Score, 28 joints with erythrocyte sedimentation rate; DAS44 Disease Activity Score, 44 joints; ETN etanercept; LDA low disease
activity;MMP-3matrix metalloproteinase 3;MTXmethotrexate;MTX-TSUmethotrexate tight step-up; NA not applicable; NR not reported; PD (ultrasound) power Doppler; SDAI Simple Disease Activity
Index; SJC swollen joint count











month treatment). There were no significant differences in
remissions between comparable groups in these trials.
Longer-term outcomes were reported for the BeSt and
Fin-RACo trials (Table 3). In the BeSt trial [46, 47], there
were similar remission rates in the four arms over 10-year
follow-up. In the FIN-RACo trial [48] at 11 years, pa-
tients receiving initial combination therapy had signifi-
cantly more remissions than with monotherapy (37% vs
19%), although there were no differences between groups
at 5 years (29% vs 22%).
Different Targets and Other Comparisons
The 10 trials reporting different targets and other comparisons
all reported remissions. Three of the four trials involving con-
ventionally treated controls reported more remissions with
intensive treatments. The CAMERA trial [17, 49, 50] (two
groups, early RA, 2-year treatment) reported significantly
more remissions with intensive than conventional treatment
(50% vs 37%, p = 0.03). The BROSG trial [18] (two groups,
established RA, 3-year treatment) also reported more remis-
sions with intensive than conventional treatment (20% vs
14%); this difference was not significant. Likewise, the
TITRATE trial [19] (two groups, established RA, 1-year treat-
ment) reported significantly more remissions with intensive
than conventional treatment (32% vs 18%). The Mueller trial
[20] compared a fixed regimen using certolizumab pegol with
a TTT regimen using certolizumab pegol, and similarly re-
ported significantly more remissions with more intensive
treatment (68% vs 29%).
Four trials compared different treatment targets. The
Hodkinson trial [37] (two groups, early RA, 12-month
treatment) compared Clinical Disease Activity Index
(CDAI) and Simple Disease Activity Index (SDAI) targets.
The Tam trial [38] (two groups, early RA, 12-month treat-
ment) compared SDAI and DAS28 remission targets. The
ARCTIC trial [39] (two groups, early RA, 24-month treat-
ment) compared a clinical target of DAS remission and no
swollen joints with an ultrasound target of no power
Doppler signal plus DAS remission and no swollen joints.
The TEAR trial [35] (four groups, early RA, 24-month
treatment) compared immediate treatment and step-up
treatment to target LDA. All four trials reported no signif-
icant difference between groups.
Fig. 2 Reported remissions at trial endpoints for TTT strategies vs standard care in rheumatoid arthritis
RA rheumatoid arthritis, TTT treat-to-target
Table 3 Long-term outcome in FIN-RACo and BeSt trials of TTT strategies in RA: remissions from 1 to 11 years
Trial Treatments Years
2 5 11
FIN-RACo [48] Single-drug treatment 18% 22% 19%
Combination treatment 37% 29% 37%
1 2 3 4 5 6 7 8 9 10
BeSt [42] Sequential monotherapy 29% 46% 48% 50% 41% 49% 49% 50% 56% 50%
Step-up combination 29% 38% 39% 40% 45% 50% 40% 56% 47% 46%
Initial prednisone combination 33% 42% 40% 39% 42% 51% 53% 57% 56% 57%
Initial infliximab combination 36% 41% 48% 41% 51% 55% 45% 47% 46% 56%
RA rheumatoid arthritis; TTT treat-to-target
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Two TTT versus conventional treatment trials (T-4 and
Optimisation of Adalimumab) also compared different treat-
ment targets. In the T-4 trial [24], matrix metallopeptidase-3
(MMP-3)-guided treatment appeared less effective than
DAS28-guided treatment. In the Optimisation of
Adalimumab trial, [26, 41] swollen joint count (SJC)-guided
treatment appeared less effective than DAS28-guided treat-
ment, although this was not statistically significant.
Disease Duration
Thirteen trials studied early RA: five compared intensive man-
agement regimens with standard care and showed significant-
ly more patients achieved remissions or LDA states with in-
tensive management (T-4 [24], BeSt [30, 51], FIN-RACo
[33], U-Act-Early [36], CAMERA [17, 49, 50]); one trial
showed more remission with intensive treatment but the dif-
ference was not significant (STREAM [25]). Another seven
early RA trials compared different intensive treatment regi-
mens and showed comparable benefits (CareRA [43],
COBRA-Light [32, 45], Saunders [34], Hodkinson [37],
TEAR [35], Tam [38], ARCTIC [39]).
Five trials studied established RA: four compared intensive
management regimens with standard care and showed signif-
icantly more patients achieved remissions or LDA states with
intensive management (Fransen [27], Optimisation of
Adalimumab [26, 41], Bergsten [28], TITRATE [19]); one
trial found more remission with intensive treatment but the
difference was not significant (BROSG [18]).
Four trials studied mixed populations of early and
established RA: two trials showed significantly more remis-
sions with intensive treatment than standard care (TICORA
[23], Mueller [20]); the other two trials showed no significant
impact of intensive treatment on LDA states (van Hulst [22],
Harrold [29]).
Adverse Events
Five trials did not report harms (Fransen [27] van Hulst [22],
BROSG [40], Hodkinson [37], Harrold [29]). Seventeen trials
variously reported deaths, serious adverse events and with-
drawals for adverse events (Table 4).
Deaths were reported in 13 trials: there were no deaths in
five trials (U-Act-Early [36], STREAM [25], Mueller [20],
Bergsten [28] and Tam [38]) and 29 deaths in the other eight
trials (BeSt [51, 52], TEAR [35], Saunders [34] T-4 [24],
TICORA [23], CareRA [44], TITRATE [19] and ARCTIC
[39]). There were four deaths in three standard care arms
and 13 deaths in 16 intensive treatment arms in which patients
received a range of intensive treatments.
Serious adverse events were reported in 13 trials; all found
some serious adverse events (TEAR [35], BeSt [30, 52],
CareRA [44], COBRA-light [45], FIN-RACo [33], U-Act-
Early [36], STREAM [25], T-4 [24], TITRATE [19],
Mueller [20], Tam [38] and ARCTIC [39]). 397/3368 (12%)
patients had a serious event: 346/2767 (13%) receiving inten-
sive management and 51/614 (8%) receiving standard care.
Serious adverse event rates varied substantially across trials:
they were greatest in the 24-month U-Act-Early trial (49/317,
15%) [36] and least in the 6-month T-4 trial [24] (5/243, 2%).
Eleven trials reported withdrawals due to adverse events.
No patients withdrew in three trials (STREAM [25], TICORA
[23], Bergsten [28] and TITRATE [19]). In seven trials
(TEAR [35], U-Act-Early [36], CAMERA [17], T-4 [24],
Optimisation of Adalimumab [26], COBRA-light [32] and
ARCTIC [39]), withdrawal rates varied substantially; they
were highest in the CAMERA trial (38/299, 13%) [50]. In
the CareRA trial [44], none of the low-risk patients withdrew
from the trial; however, various numbers of patients withdrew
from the three high-risk arms. There were 51/807 (6%) with-
drawals in seven standard care arms and 239/3009 (8%) in 30
intensive treatment arms.
Cost-Effectiveness
The heterogeneity of data in the economic literature prohibited
the construction of a single economic model that simulta-
neously compared all identified treatment strategies. Instead,
each study considered in the clinical effectiveness section was
evaluated separately. In some cases, a measure of the cost-
effectiveness was presented in the paper and could be extract-
ed; in others, sufficient data was presented to allow a measure
of incremental cost-effectiveness ratio (ICER), such as the
incremental cost per additional patient in remission, to be es-
timated assuming annual typical costs of biologic therapy of
£9200 per annum, and for simplicity assuming no costs for
csDMARDs or for RA-related hospitalisations bar rheumatol-
ogy visits, which were each assumed to cost £128 [7]. The
analyses undertaken were in line with recommendations from
NICE, which has a direct medical cost and personal social
services perspective [65]. Further details are provided in
Wailoo et al. [14]. For jurisdictions that do consider indirect
costs, such as lost productivity and costs falling upon the
individual, the ICERs would becomemore favourable to more
efficacious treatment regimens.
In nine [25, 26, 28, 29, 34, 37, 38, 41, 43, 44, 53–57] of the
22 studies, there was insufficient evidence to make any clear
conclusion regarding incremental cost-effectiveness. Further
details are provided in Wailoo et al. [14].
The 13 remaining studies [17, 22–24, 27, 30, 33, 35, 36,
40] contained sufficient evidence to allow a measure of ICER
to be estimated with some degree of confidence. In six studies,
one intervention was estimated to dominate another (greater
health-related benefits at reduced costs). From the data
contained in FIN-RACo [33], it was estimated combination
drug therapy likely dominates single-drug therapy. From the
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Table 4 Numbers of patients with adverse events in trials of treat-to-target strategies in rheumatoid arthritis
Trial Treatments Follow-up Cases Adverse events
(months) Serious Deaths Withdrawal
TEAR [35] Step-up triple therapy 24 124 16 0 4
Step-up ETN 24 255 32 2 9
Immediate triple therapy 24 132 18 1 7
Immediate ETN 24 244 35 1 12
U-Act-Early [36] MTX 24 108 13 0 8
Tocilizumab 24 103 19 0 10
Tocilizumab/MTX 24 106 17 0 9
BeSt [83] Sequential monotherapy 24 126 21 3 NR
Step-up combination 24 121 19 3 NR
Initial prednisone combination 24 133 28 2 NR
Initial infliximab combination 24 128 14 4 NR
BeSt [51] Sequential monotherapy 120 126 NR NR 16
Step-up combination 120 121 NR NR 15
Initial prednisone combination 120 133 NR NR 21
Initial infliximab combination 120 128 NR NR 20
CareRA: high-risk [43, 44, 57] COBRA Classic 24 98 21 1 12a
COBRA Slim 24 98 22 1 6a
COBRA Avant-Garde 24 93 16 0 13a
CareRA: low-risk [43, 44, 55] MTX-TSU 24 47 7 0 0a
COBRA Slim 24 43 9 0 0a
CAMERA [50] Conventional strategy 24 140 NR NR 11
Intensive strategy 24 149 NR NR 27
T-4 Study [24] Routine 12 62 1 0 6
MMP-3-driven 12 60 3 2 6
DAS28-driven 12 60 0 0 3
DAS28 and MMP-3-driven 12 61 1 0 2
Hodkinson [37] SDAI target 12 NR NR NR NR
CDAI target 12 NR NR NR NR
Fransen [27] Usual care 6 NR NR NR NR
DAS28 target 6 NR NR NR NR
Optimisation of
Adalimumab [26, 41]
Routine care 18 109 NR NR 10
SJC target 18 99 NR NR 4
DAS28 target 18 100 NR NR 12
TICORA [23] Routine 18 55 NR 3 0
Intensive 18 55 NR 1 0
Van Hulst [22] Usual care 18 NR NR NR NR
Intervention 18 NR NR NR NR
STREAM [25] Conventional 24 40 3 0 0
Aggressive 24 42 5 0 0
COBRA-Light [32] COBRA 12 81 9 NR 1
COBRA-light 12 83 16 NR 1
FIN-RACo [33] Single-drug treatment 24 98 3 NR NR
Combination treatment 24 97 5 NR NR
Saunders [34] Parallel triple therapy 12 NR NR 1 15
Step-up therapy 12 NR NR 0 18
TITRATE [19] Standard Care 12 167 10 1 0
Intensive Management 12 168 12 2 0
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evidence in the TICORA trial [23], it was estimated intensive
care dominates routine care. According to the data contained
in the Fransen trial [27] systematic monitoring dominates usu-
al care. Data from the van Hulst trial [22] implied that usual
care dominated a nurse-led approach. Mueller at al. [20]
showed that on top of a backbone of certolizumab pegol treat-
ment, a TTT approach for csDMARD treatment had signifi-
cantly better clinical outcomes than fixed csDMARD treat-
ment. Finally, data from ARCTIC [39] showed that an
ultrasound-guided tight control strategy was associated with
a statistically significant increase in bDMARD use, but that
there was no statistically significant difference in outcome
measures.
The authors calculated ICERs for the remaining seven
studies. For reference, NICE are unlikely to fund interventions
that have a cost per QALY greater than £30,000 [64]. In
TITRATE, Scott et al. [19] explicitly calculated a cost per
QALY which was £43,972 using a medical and personal so-
cial services perspective. This value became £29,363 when
indirect costs and personal costs were included, although these
aspects are not included in the NICE reference case. Using
data contained in the BROSG trial [40], an ICER for shared
care versus hospital treatment of £1517 per QALY (£7571
when baseline utility differences were considered) was esti-
mated. From evidence in CAMERA [17], it was estimated
intensive therapy would be cost-effective when compared
with conventional therapy, due to an estimated incremental
cost of £110 per patient in remission. Using data in the T-4
trial [24], basing treatment decisions on DAS28 in combina-
tion with MMP-3 was estimated to cost less than £170 per
patient in remission compared with treatments driven by
DAS28 alone, MMP-3 alone and routine care, indicating that
a combination protocol would be cost-effective [24].
Evidence from the TEAR trial [35] indicates the additional
costs associated with the immediate use of etanercept or the
use of etanercept before triple csDMARD therapy would not
be justified by the gain in health-related benefits. The higher
expense associated with initial combination therapy with
infliximab in the BeSt trial [30, 42, 46, 47, 51, 52, 58–63]
does not appear to be justified due to the lack of any signifi-
cant gain in health-related benefits compared with initial com-
bination therapy with prednisone. The evidence contained in
the U-Act-Early trial [36] indicates that a significantly higher
percentage of people treated with tocilizumab, as monothera-
py or in combination with methotrexate, achieved sustained
remission than did methotrexate monotherapy. However,
since tocilizumab is a bDMARD, it would be associated with
markedly higher costs compared with the costs associated
with methotrexate, a csDMARD, on which 44% of patients
achieved a sustained remission. The estimated ICER was a
cost of £41,818 per additional sustained remission for early
tocilizumab treatment.
Discussion
Our systematic review of 22 different trials of TTT strategies
in RA, which enrolled 5990 RA patients, provides robust ev-
idence supporting their use. Firstly, TTT strategies were effec-
tive overall; more patients achieved remission or LDA with
TTT approaches than with standard care. Secondly, there was
no evidence TTT strategies increased harms compared with
Table 4 (continued)
Trial Treatments Follow-up Cases Adverse events
(months) Serious Deaths Withdrawal
Mueller [20] Fixed regimen including
Certolizumab Pegol
6 22 1 0 NR
TTT including Certolizumab
Pegol
6 21 2 0 NR
Bergsten [28] Regular care 6 NR NR 0 0
Intervention 6 NR NR 0 0
Harrold [29] Usual care 12 NR NR NR NR
CDAI target 12 NR NR NR NR
Tam [38] SDAI target 12 57 3 0 NR
DAS28 target 12 60 3 0 NR
ARCTIC [39] Conventional tight control 24 112 7 0 5
Ultrasound tight control 24 118 6 1 7
Abbreviations: CDAI Clinical Disease Activity Index; COBRA COmBination theRApy with rheumatoid arthritis; DAS-28 Disease Activity Score, 28
joints; ETN etanercept; MMP-3 matrix metalloproteinase 3; MTX methotrexate; MTX-TSU methotrexate tight step-up; NR not reported; SDAI Simple
Disease Activity Index; SJC swollen joint count
aAE causing treatment stop
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usual care. Finally, TTT strategies were largely cost-effective.
The trials employed a wide range of different TTT strategies
and there was no evidence to favour any particular strategy;
several different approaches were equally effective. Although
TTT strategies were effective in a broad range of RA patients,
the impact of this approach was most marked in early RA.
Sixteen trials had high risk of bias, five unclear risk and one
low risk of bias.
There are several challenges evaluating TTT strategies.
Firstly, the trials involved a broad range of different treat-
ment approaches in diverse patient groups using varying
target definitions and durations. The extent of this diver-
sity precluded undertaking a meta-analysis. Secondly,
several TTT components, including treatment intensities,
treatment targets, frequent review and personalised care,
may all account for its benefits. Thirdly, although remis-
sion is the preferred target, LDA is also relevant and is
achieved by more patients. The frequency of remission
with TTT strategies also varied substantially. In two tri-
als—U-Act-Early and TICORA—most intensively-treated
patients achieved remission, but these findings were ex-
ceptional and lower numbers of patients achieved remis-
sion in the majority of trials. Finally, long-term follow-up
of two trials—BeSt and Fin-RACo—gave diverse find-
ings. In BeSt, all treatment groups had similar long-term
outcomes. In Fin-RACo, initial intensive treatment main-
tained its benefit. BeSt was undertaken in the biologic era
while Fin-RACo predated widespread biologic use; these
follow-up findings may reflect post-trial treatment differ-
ences rather than the impact of one type of TTT strategy.
Evidence that TTT approaches were cost-effective was
strongest in early RA. Conclusions about cost-effectiveness
could be made in thirteen trials. Estimates from these studies
indicated TTT was usually cost-effective; the exception was if
bDMARDs were used as the initial treatment. Initial intensive
treatment using csDMARDs appeared most cost-effective.
Health economic evaluations of the TEAR trial provided par-
ticularly strong evidence in favour of the cost-effectiveness of
initial treatment with csDMARD therapy and only using
bDMARDs when patients do not respond [65].
TTT strategies have been followed for over 10 years
[66] (Smolen, 2019). Their use is well established in RA
and is supported by many clinical guidelines; our findings
support these recommendations [67–70]. RA guidelines
are cautious about using bDMARDs as first-line therapies
and do not encourage this approach; our economic analy-
ses suggest such caution is appropriate [67–70]. Despite
the strength of support for TTT strategies, there are many
challenges implementing such approaches in routine prac-
tice. Not all specialists accept the guidance, and there are
wide variations in views on treatment and the organisation
of care approaches [71, 72]. In many centres, disease ac-
tivity is not routinely measured using quantitative
approaches [73], and not all centres have dedicated clinics
for RA patients in general and early RA in particular. A
range of additional factors influence TTT implementation
in routine practice. The frequency of visits and the value
of a 3-month assessment are important considerations
[74]. Patients’ involvement in assessing their RA may
have a crucial role using methods like the Patient-
Reported Outcomes Measurement Information System
[75]. There is also a role for training clinical staff in
TTT methods [76], although the overall impact of training
is uncertain [29].
Strengths of our systematic review include robust
searching of several databases and secondary sources, fol-
lowing PRISMA principles, undertaking independent
study selection and data extraction and assessing the qual-
ity of included studies. Heterogeneity across studies meant
we were unable to undertake pair-wise meta-analysis, with
limited assessment of publication bias. Our conclusions
also have several limitations. Firstly, there were quality
concerns about some TTT trials. Risk of bias was high in
12 conventional and four cluster trials and was only low in
TICORA [23]. Secondly, some trials had small sample
sizes and uneven baseline variable distribution, exempli-
fied by the STREAM trial [25]. Thirdly, each comparison
and population group involved relatively few trials.
Fourthly, there was heterogeneity in targets, treatment pro-
tocols, contact frequencies, outcomes and follow-up time
points. Fifthly, trials such as TEAR, treatment acceleration
and escalation in different arms complicated defining the
comparative effectiveness of the various strategies used.
Sixthly, DAS28 < 2.6 remissions do not preclude ongoing
disease activity and radiological progression, although the
ARCTIC trial [39] found no difference in remission rates
between a conventional tight control strategy aiming for
clinical remission and an ultrasound remission-guided
strategy. Finally, there are insufficient trials to be certain
TTT is cost-effective among established RA patients.
Five previous systematic reviews have combined data from
RCTs and non-randomised studies; two [9, 11] informed in-
ternational recommendations [8, 10] concluding TTT was
more effective than usual care. Assessments by Jurgens et al.
[77], Schipper et al. [78] and Bakker et al. [79] highlighted the
benefits of TTT compared with usual care. Knevel et al. [80]
found no evidence to recommend one particular target over
others in a synthesis of trials and non-randomised studies,
concluding evidence supporting TTT was limited to early
RA. Our systematic review had more stringent inclusion
criteria, only examining RCTs to minimise bias, and included
health economic assessments.
We conclude that TTT strategies are effect, safe and often
cost-effective. Their impact is most marked in early RA,
where there is strong evidence of increased remissions, and
in patient groups containing both early and established RA. In
SN Compr. Clin. Med.
established RA TTT strategies increase LDA but their impact
on remissions is less certain. The trials assessed a range of
different TTT strategies and there is no reason to prefer any
particular strategy.
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